Source: Sorapop Udomsri, Shutterstock
- A latest study has found that a single dose of the Pfizer-BioNTech or Moderna vaccine may be enough to provide immunity to COVID-19 survivors.
- The study was conducted by researchers at Los Angeles’ Cedars-Sinai Medical Center.
- In it, some 1,000 staffers participated to find out how immune reactions to the vaccines may vary among COVID survivors and others.
A latest study has found that a single dose of the Pfizer-BioNTech or Moderna vaccine may be enough to provide immunity to COVID-19 survivors.
The study was conducted by researchers at Los Angeles’ Cedars-Sinai Medical Center, where some 1,000 staffers participated in it to find out how immune reactions to the vaccines may vary among COVID survivors and others.
Why A Single Dose Of COVID-19 Vaccine Is Being Considered?
At this point, findings of this investigation could eliminate the need for a second COVID vaccine dose for those who have been infected by the SARS-CoV-2 virus. In such a scenario, authorities would be able to stretch the limited stock of COVID-19 vaccines currently available.
According to the math done by immunologist Dr Mohammad Sajadi and team at the University of Maryland School of Medicine, inoculating previously infected people with one dose of the shot could reportedly stretch the vaccine supply by over 110 million doses across the world.
At the same time, the one-dose practice could spare those with pre-existing immunity to the COVID virus the displeasure of side effects that often come with the second dose. In fact, safety concerns have been raised more than once regarding the vaccines of Johnson & Johnson’s and AstraZeneca in such cases.
©Kalkine Group 2020
A research published in the New England Journal of Medicine also points that individuals who already had the virus are likely to have a better the immune response after just one dose of the vaccine than a person who has never had COVID-19 would have after two doses.
A recent study co-authored by Dr Sajadi found that the immune system of people who have suffered from COVID-19 once “remembers” the virus and has a “strong memory response”. Because of this, a single dose of the vaccine is reportedly strong enough to boost the existing defenses.
Since February this year, in the light of side effects and safety concerns, many European countries such as France, Germany, Spain, Italy, etc have decided to administer a single dose of COVID-19 vaccines instead of two to people who have survived the disease.